UNSPSC 51314383: Acetaminophen/chlorpheniramine/dextromethorphan/phenylephrine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE506. This VA Drug Class (RE506) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT/ANTITUSSIVE/ANALGESIC.

The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate.

UNSPSC 51314383 Acetaminophen/chlorpheniramine/dextromethorphan/phenylephrine is a Commodity code that, based on recent state and local procurement activity, maps poorly to actual purchasing under this designation. The code nominally describes a specific combination pharmaceutical product, yet recent solicitations tagged to it cover broader pharmaceutical and OTC product procurement, naloxone and drug deactivation systems, and direct-to-manufacturer prescription fulfillment programs—scopes that extend well beyond the narrow product combination the code name implies. State and local governments issuing opportunities under this code include county health agencies, state health and human services departments, and multistate cooperative purchasing alliances. Seminole County, Florida; the Texas Health and Human Services Commission; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) represent the issuing bodies present in recent activity.

Recent procurement under the code spans Florida, Texas, and Minnesota. Seminole County released IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023, through competitive sealed bidding. The Texas HHS Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor intelligence on direct-to-manufacturer prescription programs and therapeutic pharmacy initiatives, representing exploratory procurement activity rather than a formal solicitation. The Minnesota Department of Administration's MMCAP issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products across participating state and local facilities, with a response deadline of March 26, 2026 and contract effectiveness targeted for July 1, 2026. The code's recent activity suggests misalignment between its nominal scope and actual procurement—business development professionals should verify whether this specific pharmaceutical combination is the intended target before pursuing opportunities tagged to this code.